Armodafinil
- Generic Name
- Armodafinil
- Brand Names
- Nuvigil
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15NO2S
- CAS Number
- 112111-43-0
- Unique Ingredient Identifier
- V63XWA605I
- Background
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patient...
- Indication
用于改善与阻塞性睡眠呼吸暂停（OSA）、发作性睡病或轮班工作障碍（SWD）相关的过度嗜睡的成年患者的清醒度。亦可用于治疗注意缺陷多动障碍、慢性疲劳综合征和重度抑郁症。
- Associated Conditions
- Narcolepsy, Shift-work related sleep disturbance, Somnolence
- Associated Therapies
- -
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
- Conditions
- Interventions
- First Posted Date
- 2007-08-21
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 249
- Registration Number
- NCT00518986
- Locations
- 🇺🇸
The Sleep Disorders Center, Atlanta, Georgia, United States
🇺🇸CRI Worldwide, Philadelphia, Pennsylvania, United States
🇺🇸Sleep Medicine Associates of Texas, P.A., Dallas, Texas, United States
Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits
- First Posted Date
- 2007-06-19
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 60
- Registration Number
- NCT00487942
- Locations
- 🇺🇸
CNRI-Los Angeles, LLC, Pico Rivera, California, United States
🇺🇸Atlanta Center for Clinical Research, Atlanta, Georgia, United States
🇺🇸Collaborative NeuroScience Network, Garden Grove, California, United States
Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 257
- Registration Number
- NCT00481195
- Locations
- 🇺🇸
Janus Center for Psychiatric Research, West Palm Beach, Florida, United States
🇺🇸Dubois Regional Medical Center - Behavioral Health Services, Dubois, Pennsylvania, United States
🇺🇸CNRI Los Angeles LLC, Pico Rivera, California, United States
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
- Conditions
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 247
- Registration Number
- NCT00228566
- Locations
- 🇺🇸
Sleepmed Inc., Macon, Georgia, United States
🇺🇸Savannah Neuurology, Savannah, Georgia, United States
🇺🇸Evanston Northwestern Healthcare, Evanston Hospital, Evanston, Illinois, United States
Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With Narcolepsy
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2013-07-19
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 196
- Registration Number
- NCT00078377
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.